A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

This study is ongoing, but not recruiting participants.

First Received: April 23, 2008 Last Updated: January 9, 2009 History of Changes

Sponsored by:	Dow Pharmaceutical Sciences
Information provided by:	Dow Pharmaceutical Sciences
ClinicalTrials.gov Identifier:	NCT00666900

Purpose

The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Condition	Intervention	Phase
Acne Vulgaris	Drug: Low Strength IDP-107 Drug: High Strength IDP-107 Drug: Placebo Comparator	Phase II

MedlinePlus related topics: Acne

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Dow Pharmaceutical Sciences:

Primary Outcome Measures:

Change from baseline in the number of inflammatory lesions [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Improvement from baseline in global severity [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change from baseline in the number of non-inflammatory lesions [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment:	366
Study Start Date:	January 2008
Estimated Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Low Strength IDP-107 Once a day for 12 weeks
2: Experimental	Drug: High Strength IDP-107 Once a day for 12 weeks
3: Placebo Comparator	Drug: Placebo Comparator Once a day for 12 weeks

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Dermatological conditions of the face that could interfere with clinical evaluations
Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00666900

Sponsors and Collaborators

Dow Pharmaceutical Sciences

More Information

No publications provided

Responsible Party:	Dow Pharmaceutical Sciences, Inc. ( Barry M. Calvarese, MS / Vice President, Regulatory & Clinical Affairs )
Study ID Numbers:	DPSI-IDP-107-P2-01
Study First Received:	April 23, 2008
Last Updated:	January 9, 2009
ClinicalTrials.gov Identifier:	NCT00666900 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Exanthema
Facial Dermatoses
Facies

Skin Diseases
Sebaceous Gland Diseases
Acne Vulgaris

Additional relevant MeSH terms:

Facial Dermatoses
Skin Diseases
Acneiform Eruptions
Sebaceous Gland Diseases
Acne Vulgaris

ClinicalTrials.gov processed this record on May 07, 2009